Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
To determine the maximum tolerated dose of, and response to, PRLX 93936 as treatment for patients with relapsed or relapsed/refractory multiple myeloma.
Multiple Myeloma
DRUG: PRLX 93936
Maximum Tolerated Dose, Cycle 1 (28 days from first dose)
Response to treatment, Each cycle (assessed every 28 days starting from first dose, for up to 8 months)|Time to response, From date of first dose to date of response, assessed up to 8 months|Duration of response, From date of response to first documented progression or death, or date last known progression-free and alive at study discontinuation, assessed up to 8 months|Time to progression, From date of first dose to first documented progression, assessed up to 8 months
* To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLT) of PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks followed by a 9 day rest period, as treatment for patients with relapsed or relapsed/refractory multiple myeloma.
* To establish the dose of PRLX 93936 recommended for future studies.
* To characterize potential toxicities of PRLX 93936.
* To assess the pharmacokinetic profile of PRLX 93936.
* To evaluate response to treatment, time to response (TTR) and duration of response.
* To evaluate time to progression (TTP).